Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
Fiche publication
Date publication
septembre 2007
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D
Lien Pubmed
Résumé
This randomized, double-blind, placebo-controlled phase III study aimed to determine whether thalidomide prolongs survival of patients with extensive-disease small-cell lung cancer (SCLC).
Mots clés
Carcinoma, Small Cell, drug therapy, Disease-Free Survival, Double-Blind Method, Female, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Proportional Hazards Models, Survival Rate, Thalidomide, therapeutic use
Référence
J. Clin. Oncol.. 2007 Sep;25(25):3945-51